|
1
|
Burger M, Catto J, Dalbagni G, Grossman
HB, Herr H, Karakiewicz P, Kassouf W, Kiemeney LA, La Vecchia C,
Shariat S and Lotan Y: Epidemiology and risk factors of urothelial
bladder cancer. Eur Urol. 63:234–241. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Boccardo F and Palmeri L: Adjuvant
chemotherapy of bladder cancer. Ann Oncol. 17:(Suppl 5). v129–v132.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Stein JP, Lieskovsky G, Cote R, Groshen S,
Feng AC, Boyd S, Skinner E, Bochner B, Thangathurai D, Mikhail M,
et al: Radical cystectomy in the treatment of invasive bladder
cancer: Long-term results in 1054 patients. J Clin Oncol.
19:666–675. 2001.PubMed/NCBI
|
|
4
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–301. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fiscella M, Zhang H, Fan S, Sakaguchi K,
Shen S, Mercer WE, Woude GF Vande, O'Connor PM and Appella E: Wip1,
a novel human protein phosphatase that is induced in response to
ionizing radiation in a p53-dependent manner. Proc Natl Acad Sci
USA. 94:6048–6053. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhang L, Chen LH, Wan H, Yang R, Wang Z,
Feng J, Yang S, Jones S, Wang S, Zhou W, et al: Exome sequencing
identifies somatic gain-of-function PPM1D mutations in brainstem
gliomas. Nat Genet. 46:726–730. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Richter M, Dayaram T, Gilmartin AG, Ganji
G, Pemmasani SK, Van Der Key H, Shohet JM, Donehower LA and Kumar
R: Wip1 phosphatase as a potential therapeutic target in
neuroblastoma. PLoS One. 10:e01156352015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sun GG, Zhang J, Ma XB, Wang YD, Chen YJ
and Hu WN: Overexpression of wild-type p53-induced phosphatase1
confers poor prognosis of patients with nasopharyngeal carcinoma.
Pathol Oncol Res. 21:283–291. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li GB, Zhang XL, Yuan L, Jiao QQ, Liu DJ
and Liu J: Protein phosphatase magnesium-dependent 1δ (PPM1D) mRNA
expression is a prognosis marker for hepatocellular carcinoma. PLoS
One. 8:e607752013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sobin L, Gospodarowicz M and Wittekind C:
TNM classification of malignant tumorsUICC International Union
Against Cancer. 7th. Wiley-Blackwell; pp. 262–265. 2009
|
|
11
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Witjes JA, Compérat E, Cowan NC, De Santis
M, Gakis G, Lebret T, Ribal MJ, Van der Heijden AG and Sherif A:
European Association of Urology: EAU guidelines on muscle-invasive
and metastatic bladder cancer: Summary of the guidelines. Eur Urol.
65:778–792. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shreeram S, Demidov ON, Hee WK, Yamaguchi
H, Onishi N, Kek C, Timofeev ON, Dudgeon C, Fornace AJ, Anderson
CW, et al: Wip1 phosphatase modulates ATM-dependent signaling
pathways. Mol Cell. 23:757–764. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lu X, Nannenga B and Donehower LA: PPM1D
dephosphorylates Chk1 and p53 and abrogates cell cycle checkpoints.
Genes Dev. 19:1162–1174. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fujimoto H, Onishi N, Kato N, Takekawa M,
Xu XZ, Kosugi A, Kondo T, Imamura M, Oishi I, Yoda A and Minami Y:
Regulation of the antioncogenic Chk2 kinase by the oncogenic Wip1
phosphatase. Cell Death Differ. 13:1170–1180. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lu X, Nguyen TA, Moon SH, Darlington Y,
Sommer M and Donehower LA: The type 2C phosphatase Wip1: An
oncogenic regulator of tumor suppressor and DNA damage response
pathways. Cancer Metastasis Rev. 27:123–135. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lowe J, Cha H, Lee MO, Mazur SJ, Appella E
and Fornace AJ Jr: Regulation of the Wip1 phosphatase and its
effects on the stress response. Front Biosci (Landmark Ed).
17:1480–1498. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Marcel V, Dichtel-Danjoy ML, Sagne C,
Hafsi H, Ma D, Ortiz-Cuaran S, Olivier M, Hall J, Mollereau B,
Hainaut P and Bourdon JC: Biological functions of p53 isoforms
through evolution: Lessons from animal and cellular models. Cell
Death Differ. 18:1815–1824. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Pfister C, Flaman JM, Dunet F, Grise P and
Frebourg T: p53 mutations in bladder tumors inactivate the
transactivation of the p21 and Bax genes, and have a predictive
value for the clinical outcome after bacillus Calmette-Guerin
therapy. J Urol. 162:69–73. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Crescenzi E, Raia Z, Pacifico F, Mellone
S, Moscato F, Palumbo G and Leonardi A: Down-regulation of
wild-type p53-induced phosphatase 1 (Wip1) plays a critical role in
regulating several p53-dependent functions in premature senescent
tumor cells. J Biol Chem. 288:16212–16224. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lu X, Ma O, Nguyen TA, Jones SN, Oren M
and Donehower LA: The Wip1 phosphatase acts as a gatekeeper in the
p53-Mdm2 autoregulatory loop. Cancer Cell. 12:342–354. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jiao L, Shen D, Liu G, Jia J, Geng J, Wang
H and Sun Y: PPM1D as a novel biomarker for prostate cancer after
radical prostatectomy. Anticancer Res. 34:2919–2925.
2014.PubMed/NCBI
|
|
23
|
Satoh N, Maniwa Y, Bermudez VP, Nishimura
K, Nishio W, Yoshimura M, Okita Y, Ohbayashi C, Hurwitz J and
Hayashi Y: Oncogenic phosphatase Wip1 is a novel prognostic marker
for lung adenocarcinoma patients survival. Cancer Sci.
102:1101–1106. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sun GG, Wang YD, Liu Q and Hu WN:
Expression of Wip1 in kidney carcinoma and its correlation with
tumor metastasis and clinical significance. Pathol Oncol Res.
21:219–224. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang HY, Liu ZS, Qiu L, Guo J, Li YF,
Zhang J, Wang TJ and Liu XD: Knockdown of Wip1 enhances sensitivity
to radiation in HeLa cells through activation of p38 MAPK. Oncol
Res. 22:225–233. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wagner U, Sauter G, Moch H, Novotna H,
Epper R, Mihatsch MJ and Waldman FM: Patterns of p53, erbB-2, and
EGF-r expression in premalignant lesions of the urinary bladder.
Hum Pathol. 26:970–978. 1995. View Article : Google Scholar : PubMed/NCBI
|
